🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Honored to share our Journal of the @NCCN review on biomarker-driven approaches for Metastatic Gastric Cancer doi.org/10.6004/jnccn.… Grateful for the amazing guidance and mentorship of Rutika Mehta #GastricCancer #OncologyResearch

Much needed work in the field. Congratulations Ben Derman and the whole team.

Congratulations to ⁦Frederick L. Locke⁩ on winning the ⁦Moffitt Cancer Center⁩ Researcher of the Year Award and giving a virtuoso overview of his achievements over the past 10 years! With ⁦Mihaela Druta⁩

Ahead of #ASCO25, Taiga Nishihori, MD, (Taiga Nishihori, MD) highlights a groundbreaking study by Mass General Brigham presented at ASCO on a digital psychosocial app supporting caregivers of patients undergoing hematopoietic stem cell transplantation. Learn more: bit.ly/4khFRSZ

Proud Mentee Moment! Andrew Kuykendall MD presenting the practice-changing VERIFY Trial using #Rusfertide for #PolycythemiaVera during an exceptional Plenary Session at ASCO Moffitt Cancer Center OncoDaily

🚨 Exercise is no longer optional, it is essential! One of the most impactful studies at #ASCO25 🏃‍♂️ The #CHALLENGE trial (LBA4319) proves that structured exercise after chemo in stage III colon cancer is not just lifestyle—it’s life-saving. 📊 5y DFS: 80.3% vs 73.9% ❤️ 8y OS:

Just out at Journal of Clinical Oncology: COALITION study comparing glofitamab + PolaR-CHP vs glofit-R-CHOP in frontline large B cell lymphoma - very exciting n=80 ORR 100% CRR 98% 21 month PFS 86%, OS 92% ascopubs.org/doi/10.1200/JC… Congrats Michael Dickinson Adrian Minson ! #lymsm #18ICML

ICML25: Outpatient fixed duration Mosun-Pola regimen is highly efficacious in 3L+ R/R MCL in this phase 2 cohort: 71% had 3+ high risk features (prior CAR, ASCT, TP53, Blastoid/pleomorphic, Ki67 30%+ etc). ORR 88%, CR79% CRS all low grade and resolved.

👉Here is an updated version of the Table which I initially posted post ASH2024. 👉Now Updated with EHA 2025 data including updated FLAIR, CLL13, CAPTIVATE trials. #CLL

Thrilled to share our 3‑year follow‑up results from the phase III TRANSFORM trial of lisocabtagene maraleucel vs standard of care in 2L R/R LBCL⁩ 🎉 ⁦CU Cancer Center⁩ ⁦⁩ ⁦CU Anschutz Division of Hematology⁩ ⁦Lymphoma Research Foundation⁩ ⁦Women in Lymphoma - [email protected]⁩⁦ ascopubs.org/doi/10.1200/JC…

Join us in congratulating Moffitt Cancer Center President and CEO, Patrick Hwu, MD, for being recognized by his peers and the Tampa Bay Business Journal as one of Tampa Bay’s 2025 Most Admired CEOs. This recognition reflects his leadership in advancing Moffitt as Florida’s

"These findings show that we do have alternatives for those patients now that are relatively well tolerated and have a high CR rate," said Julie Vose on results from the phase 2 EPCORE NHL-1 trial. #lymsm hubs.li/Q03w6CpH0

🎗️July is Sarcoma Awareness Month, and I'm so proud of the progress we’re making! At Moffitt Cancer Center, we were part of the pivotal trial that led to the first genetically modified T-cell therapy for synovial sarcoma and treated the first patient in the world. #sarcomaawarenessmonth

Excellent review article!

Amazing work led by Rahul Banerjee, MD, FACP !

A powerful reminder of why real-world data matters—this study shows how it drives real impact in healthcare!

MCL treatment has improved over the last decade but there are still challenging cases of relapsed MCL despite all the advances in treatment options !

🔁 Re-sharing a study from our group on long-term outcomes in adult LCH 🧬 Clinical phenotypes, treatment patterns, and prognostic factors 📊 219 adults | ↑ mortality vs general population esp. among <55y and multi-system disease 🔗 tinyurl.com/yvdry9ms #LCH #RareDiseases

🚨 A Phase I/II Trial of Ruxolitinib with Chemotherapy for Patients with Relapsed and/or Refractory Philadelphia-like Acute Lymphoblastic Leukemia - Clinical Lymphoma, Myeloma and Leukemia clinical-lymphoma-myeloma-leukemia.com/article/S2152-… | Hannah Goulart Marina Konopleva Nitin Jain #leusm #endcancer

Our manuscript using single cell RNA sequencing to compare two CD19 CAR T cell products, axi-cel and tisa-cel is online at JITC! Frederick L. Locke Moffitt Cancer Center jitc.bmj.com/content/13/7/e… . Our findings (thread):